GR 103691, ,> 98 %( HPLC ), solide

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

GR 103691 has been used as a D3 receptor antagonist to test its:inducing effect on prepulse inhibition (PPI)suppressive effect of motor behavior in ratsinhibitory effect on chemotaxis in newly excysted juvenile C. sinensis (CsNEJs)

Biochem/physiol Actions

D₃ dopamine receptor antagonist.

GR 103691 increases the monosynaptic “stretch” reflex (MSR) amplitude in mice by its potent D3 receptor antagonist functionality. It inhibits the PD 128,907 mediated γ-aminobutyric acid (GABA) release.

Features and Benefits

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

10 mg in glass bottle